BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 19670957)

  • 1. Medicare part D after 2 years.
    Joyce GF; Goldman DP; Vogt WB; Sun E; Jena AB
    Am J Manag Care; 2009 Aug; 15(8):536-44. PubMed ID: 19670957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017.
    Bartlett VL; Liu P; Dhruva SS; Shah ND; Bollinger KE; Ross JS
    J Manag Care Spec Pharm; 2020 Apr; 26(4):562-567. PubMed ID: 32223594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
    Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
    JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
    Blumberg DM; Prager AJ; Liebmann JM
    JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coverage for hepatitis C drugs in Medicare Part D.
    Jung JK; Feldman R; Cheong C; Du P; Leslie D
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription Drug Spending in Fee-for-Service Medicare, 2008-2019.
    Dusetzina SB; Huskamp HA; Qin X; Keating NL
    JAMA; 2022 Oct; 328(15):1515-1522. PubMed ID: 36255428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Medicare Part D on Prescription Drug Spending and Health Care Use: 6 Years of Follow-up, 2007-2012.
    Park T; Jung J
    J Manag Care Spec Pharm; 2017 Jan; 23(1):5-12. PubMed ID: 28025927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescription coverage, use and spending before and after Part D implementation: a national longitudinal panel study.
    Safran DG; Strollo MK; Guterman S; Li A; Rogers WH; Neuman P
    J Gen Intern Med; 2010 Jan; 25(1):10-7. PubMed ID: 19882193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
    DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
    JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Comprehensive Medication Review Acceptance by Using a Standardized Recruitment Script: A Randomized Control Trial.
    Miguel A; Hall A; Liu W; Garrett J; Ballew A; Yang TH; Segal R
    J Manag Care Spec Pharm; 2017 Jan; 23(1):13-21. PubMed ID: 28025924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Medicare Part D on drug affordability and use: Are seniors with prior high out-of-pocket drug spending affected more?
    Mott DA; Thorpe JM; Thorpe CT; Kreling DH; Gadkari AS
    Res Social Adm Pharm; 2010 Jun; 6(2):90-9. PubMed ID: 20511108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growing Number Of Unsubsidized Part D Beneficiaries With Catastrophic Spending Suggests Need For An Out-Of-Pocket Cap.
    Trish E; Xu J; Joyce G
    Health Aff (Millwood); 2018 Jul; 37(7):1048-1056. PubMed ID: 29985706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage.
    McWilliams JM; Zaslavsky AM; Huskamp HA
    JAMA; 2011 Jul; 306(4):402-9. PubMed ID: 21791689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of Medicare Part D on drug and medical spending.
    Zhang Y; Donohue JM; Lave JR; O'Donnell G; Newhouse JP
    N Engl J Med; 2009 Jul; 361(1):52-61. PubMed ID: 19571283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year impact of Medicare Part D coverage gap reform on drug expenditures and utilization.
    Park J; Look KA
    Health Serv Res; 2022 Feb; 57(1):56-65. PubMed ID: 33870486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription Drug Spending and Medication Adherence Among Medicare Beneficiaries with Heart Failure.
    McGee BT; Phillips V; Higgins MK; Butler J
    J Manag Care Spec Pharm; 2019 Jun; 25(6):705-713. PubMed ID: 31134861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Federal and Individual Spending on the 10 Costliest Medications in Medicare Part D from 2011 to 2015.
    Watanabe JH; Chau DL; Hirsch JD
    J Am Geriatr Soc; 2018 Aug; 66(8):1621-1624. PubMed ID: 29972589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Medicare Part D on the Proportion of Out-of-Pocket Prescription Drug Costs Among Older Adults With Diabetes.
    Choi YJ; Jia H; Gross T; Weinger K; Stone PW; Smaldone AM
    Diabetes Care; 2017 Apr; 40(4):502-508. PubMed ID: 27803119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.